Vanguards of Healthcare: AstraZeneca’s Oncology Playbook
“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at...
By Inigo Imaz Blanco · Bloomberg
“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in